|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The secretion of BAFF was tested in patients with MM, MM cell lines, and macrophages.
|
29095438 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was positive correlation between APRIL and BAFF concentration in multiple myeloma (P=0.0027).
|
28928810 |
2017 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was found that miR-202 was functioned as a modulator of BAFF expression. miR-202 over-expression sensitized MM cells to bortezomib (Bort) but less to Thalidomide (Thal) and dexamethasone (Dex). miR-202 mimics in combination with Bort inhibited MM cell survival more effectively as compared with Bort treatment alone.
|
26689580 |
2016 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review discusses the role of BAFF in the pathophysiology of MM, and the potential of BAFF-inhibitory therapy for the treatment of MM.
|
25723853 |
2015 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma.
|
26339644 |
2015 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that JNK activation and BLyS expression in MM cells may form a positive feedback loop that promotes the survival and proliferation of MM cells, and these may shed some light on the pathogenesis and treatment of MM.
|
22850273 |
2012 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was shown that NFkB activation in MM tumors results mainly from extrinsic signaling by APRIL and BAFF ligands that stimulate receptors on normal plasma cells as well as on pre-malignant monoclonal gammopathy of undetermined significance (MGUS) and MM tumors.
|
20890394 |
2010 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
More importantly, 93.55% (29/31) and 90.32% (28/31) of these MM patients had significantly higher expression levels of BLyS and BCMA mRNA respectively, which are correlated with the levels of LDH, while 64.52% (20/31) of these MM patients had significantly lower expression levels of TACI mRNA.
|
19028483 |
2009 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, linear correlation analysis of the Lactate Dehydrogenase concentration and beta 2-microglobulin level with BLyS, and expressions of BLyS mRNA in MM patients revealed a significant correlation between them (P < 0.01 in all case), showing that BLyS could be a biomarker for the diagnosis and treatment of MM.
|
19187273 |
2009 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data show a role for BAFF as a survival factor in MM.
|
17908986 |
2007 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Our data show a role for BAFF as a survival factor in MM.
|
17908986 |
2007 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAFF and APRIL stimulate the growth of multiple myeloma (MM) cells.
|
17550853 |
2007 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
LHGDN |
These studies establish a role for BAFF in localization and survival of multiple myeloma cells in the bone marrow microenvironment and strongly support novel therapeutics, targeting the interaction between BAFF and its receptors in human multiple myeloma.
|
16818641 |
2006 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) have been shown to promote multiple myeloma (MM) cell growth.
|
15827134 |
2005 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.
|
14512299 |
2004 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Altogether, these data suggest that APRIL/BAFF inhibitors may be of clinical value in MM.
|
15070697 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, these data suggest that APRIL/BAFF inhibitors may be of clinical value in MM.
|
15070697 |
2004 |